Company news

Eton Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Eton Pharmaceuticals to Report Fourth Quarter 2021 Financial Results on Wednesday, March 16, 2022

March 7, 2022

Eton Pharmaceuticals and ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First and Only FDA-Approved Generic Version of Carbaglu® (carglumic acid)

December 19, 2021

Eton Pharmaceuticals Reports Third Quarter Financial Results

November 14, 2021

Eton Pharmaceuticals Announces Co-Promotion Agreement with Tolmar Pharmaceuticals for ALKINDI SPRINKLE®

November 14, 2021

Eton Pharmaceuticals and Azurity Pharmaceuticals, Inc. Announce FDA Approval of EPRONTIA™ (topiramate) Oral Solution

November 7, 2021

Eton Pharmaceuticals to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021

November 2, 2021

Eton Pharmaceuticals Announces Acquisition of Approved Orphan Drug Product Carglumic Acid

October 27, 2021

Eton Pharmaceuticals Reports Second Quarter Financial Results

August 15, 2021

Eton Pharmaceuticals to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021

August 2, 2021

Eton Pharmaceuticals Announces FDA Approval of Rezipres® (Ephedrine Hydrochloride Injection)

June 14, 2021

Eton Pharmaceuticals Acquires U.S. and Canadian Rights to ZENEO® Hydrocortisone Autoinjector

June 14, 2021

Eton Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Dehydrated Alcohol Injection

May 27, 2021

Eton Pharmaceuticals Reports Record Revenue and Earnings

May 12, 2021

Eton Pharmaceuticals to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021

May 3, 2021

Eton Pharmaceuticals Announces Appointment of Jenn Adams to its Board of Directors

March 16, 2021

Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Financial Results

March 15, 2021

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 16, 2021

March 3, 2021

Eton Pharmaceuticals to Participate in 10th Annual SVB Leerink Global Healthcare Conference

February 15, 2021

Eton Pharmaceuticals Announces Sale of Neurology Portfolio

February 7, 2021

Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI® SPRINKLE

January 13, 2021

Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Topiramate Oral Solution

December 16, 2020

Eton Pharmaceuticals Announces Availability of Orphan Drug ALKINDI® SPRINKLE (hydrocortisone) in the United States

November 23, 2020

Eton Pharmaceuticals Announces Third Quarter 2020 Financial Results

November 11, 2020

Eton Pharmaceuticals to Report Third Quarter Financial Results on Thursday, November 12, 2020

November 3, 2020

Eton Pharmaceuticals Announces Closing of Public Offering

October 15, 2020

Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Zonisamide Oral Suspension

October 14, 2020

Eton Pharmaceuticals Prices Underwritten Public Offering of Common Stock

October 13, 2020

Eton Pharmaceuticals Announces Proposed Public Offering of Common Stock

October 12, 2020

Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Orphan Drug Dehydrated Alcohol Injection

October 7, 2020

Eton Pharmaceuticals Submits New Drug Application to the FDA for Topiramate Oral Solution (ET-101)

October 5, 2020

Eton Pharmaceuticals Announces FDA Approval of Orphan Drug ALKINDI® SPRINKLE (hydrocortisone) as Replacement Therapy in Pediatric Patients with Adrenocortical Insufficiency

September 28, 2020

Eton Pharmaceuticals Provides Update on the FDA Review of EM-100

September 15, 2020

Eton Pharmaceuticals Announces Appointment of Ingrid Hoos as Senior Vice President of Scientific Affairs

August 30, 2020

Eton Pharmaceuticals Announces Second Quarter 2020 Financial Results

August 11, 2020

Eton Pharmaceuticals to Report Second Quarter Financial Results on Wednesday, August 12, 2020

August 3, 2020

Eton Pharmaceuticals Submits New Drug Application to the FDA for Zonisamide Oral Suspension (ET-104)

July 29, 2020

Eton Pharmaceuticals Submits New Drug Application to the FDA for Orphan Drug Dehydrated Alcohol Injection (DS-100)

July 26, 2020

Eton Pharmaceuticals Announces First Quarter 2020 Financial Results

May 13, 2020

Eton Pharmaceuticals Confirms First-to-File Patent Challenge on Elcys (Cysteine Hydrochloride Injection)

May 6, 2020

Eton Pharmaceuticals to Report First Quarter Financial Results on Thursday, May 14, 2020

May 5, 2020

Eton Pharmaceuticals Announces Appointment of Paul Stickler as Senior Vice President of Sales and Marketing

May 3, 2020

Eton Pharmaceuticals Announces Acquisition of U.S Marketing Rights to Pediatric Orphan Drug Alkindi® Sprinkle

March 26, 2020

Eton Pharmaceuticals Reports Positive Study Results for ET-101 (Topiramate Oral Solution)

March 16, 2020

Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results

March 4, 2020

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 5, 2020

February 26, 2020

Eton Pharmaceuticals Provides Update on ET-105 Program

February 18, 2020

Eton Pharmaceuticals to Present at the 9th Annual SVB Leerink Healthcare Conference

February 12, 2020

Eton Pharmaceuticals and Xellia Pharmaceuticals Announce Biorphen® (phenylephrine HCl) Co-Promotion Agreement

January 20, 2020

Eton Pharmaceuticals Announces Commercial Availability of Biorphen® (phenylephrine HCI) Injection

December 1, 2019

Eton Pharmaceuticals Announces Third Quarter Financial Results and Highlights Business Progress

November 13, 2019

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 6 decks. Every deck is listed under its year.